In Vitro Antimicrobial Pharmacokinetics/Pharmacodynamics
OPTIMIZING THERAPY FOR MULTIDRUG-RESISTANT PATHOGENS
The in vitro PK/PD research of the Section of Infectious Diseases Pharmacotherapy focuses on discovering optimal antimicrobial treatment regimens against extensively drug resistant bacterial pathogens. Our current work evaluates synergistic antimicrobial combination treatment regimens against emerging super resistant Gram-negative pathogens such as those harboring metallo-beta-lactamase and/or class D serine beta-lactamases. Additionally our laboratories have begun to incorporate genomic analyses to help study bacterial resistance.
Our long term goal is to design personalized antimicrobial treatment regimens based on the pathogen’s genotypic-phenotypic background and patient-specific factors.
The clinical pharmacokinetics research of the Section of Infectious Diseases Pharmacotherapy investigates antimicrobial pharmacokinetics. Studies are conducted for novel dosing regimens in healthy volunteers and in special patient populations including critically ill patients and those receiving forms of hemodialysis, and antimicrobial penetration to target body sites such as the epithelial lining fluid of the lungs.
Clinical and Translational Outcomes Research
The clinical and translational outcomes research of the Section of Infectious Diseases Pharmacotherapy attempts to translate and apply the in vitro and clinical research findings to patients afflicted with infectious disease syndromes. More specifically, we are exploring the impact of bacterial genotypic-phenotypic relationships on the clinical outcomes of patients infected with resistant pathogens.